New insights into the pharmacological properties of potent antiplatelet 2-amino-benzo[d]isothiazol-3-one derivatives

Pharmacological Research

Volumn 46, Issue 5, 2002, Pages 389-393

  Ballabeni, Vigilio ^a   Tognolini, Massimiliano ^a   Calcina, Francesco ^a   Impicciatore, Mariannina ^a   Vicini, Paola ^a   Barocelli, Elisabetta ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

Antiplatelet drugs; Benzoisothiazolone; Bleeding; Experimental thrombosis; Subacute treatment

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ADRENALIN; ANTITHROMBOCYTIC AGENT; COLLAGEN; ISOTHIAZOLE DERIVATIVE; LYSINE ACETYLSALICYLATE; 2 AMINO BENZO(D)ISOTHIAZOL 3 ONE; 2-AMINO-BENZO(D)ISOTHIAZOL-3-ONE; CHOLINERGIC RECEPTOR BLOCKING AGENT; THIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG SCREENING; DRUG TOLERABILITY; IN VITRO STUDY; IN VIVO STUDY; LUNG EMBOLISM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE RICH PLASMA; THROMBOSIS; ULCEROGENESIS; ANIMAL; CHEMICALLY INDUCED DISORDER; CHEMISTRY; GUINEA PIG; ILEUM; INTRAPERITONEAL DRUG ADMINISTRATION; LD 50; MUSCLE CONTRACTION; ORAL DRUG ADMINISTRATION; PEPTIC ULCER; PHYSIOLOGY; SMOOTH MUSCLE; THROMBOCYTE AGGREGATION;

ADMINISTRATION, ORAL; ANIMALS; BLEEDING TIME; GUINEA PIGS; ILEUM; INJECTIONS, INTRAPERITONEAL; LETHAL DOSE 50; MALE; MICE; MUSCLE CONTRACTION; MUSCLE, SMOOTH; PARASYMPATHOLYTICS; PEPTIC ULCER; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PULMONARY EMBOLISM; THIAZOLES;

EID: 0036433112     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043661802002086     Document Type: Article

References (25)

1. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of platelet therapy. I. Prevention of death, infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-106.
2. Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R. Second International Study of Infarct Survival (ISIS-2 Collaborative group): 10 years survival among patients with suspected acute myocardial infarction in randomized comparison of intravenous streptokinase, oral aspirin, both or neither. Br Med J 1998; 316: 1337-43.
3. Tisdale JE. Antiplatelet therapy in coronary artery disease: Review and update of efficacy studies. Am J Health-Syst Pharm 1998; 55(Suppl): S8-16.
4. Patrono C. Aspirin as antiplatelet drug. New Engl J Med 1994; 330: 1287-94.
5. Guslandi M. Gastric toxicity of antiplatelet therapy with low dose aspirin. Drugs 1997; 53: 1-5.
6. Vicini P, Manotti C, Caretta A, Amoretti L. Synthesis and antiplatelet effects of 2-amino-1,2-benziso-thiazolin-3-one. Arzneimittelforschung 1997; 47: 1218-21.
7. Vicini P, Manotti C, Caretta A, Amoretti L. Comparison of in vitro and ex vivo antiplatelet effects of 1,2-benzisothiazolin-3-one and its 2-amino derivative. Arzneimittelforschung 1999; 49: 896-9.
8. Vicini P, Amoretti L, Ballabeni V, Tognolini M, Barocelli E. 2-Amino-1,2-benzisothiazolin-3-one derivatives: Synthesis and assessement of their antiplatelet/spasmolytic effects. Bioorg Med Chem 2000; 8: 2355-8.
9. Momo K, Someya K, Tachiiri T, Mitsuoka Y, Nakamura K, Imai S, Ino T, Ohkubo H. Effects of the new antiplatelet agent 2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine on platelet aggregation and thrombosis in experimental animals. Arzneimittelforschung 1992; 42: 32-9.
10. DiMinno G. Mouse antithrombotic assay: A simple method for the evaluation of antithrombotic agents in vivo. Potentiation of antithrombotic activity by ethyl alcohol. J Pharmacol Exp Ther 1983; 225: 57-60.
11. Dejana E, Callioni A, Quintana A, De Gaetano G. Bleeding time in laboratory animals. II. A comparison of different assay conditions in rats. Thromb Res 1979; 15: 191-7.
12. Rainsford KD. Gastric ulcerogenicity of non-steroidal anti-inflammatory drugs in mice with mucosa sensitized by cholinomimetic treatment. J Pharm Pharmacol 1987; 39: 669-72.
13. Burn JH, Finney DJ, Goodwin LG. Biological standardization. London, New York: Oxford University Press, 1952.
14. Born GVR. Aggregation by ADP and its reversal. Nature 1962; 194: 927-9.
15. Furchgott RF. In: Blanschko H, Muscholl E, eds. Handbook of experimental pharmacology, vol. 33. New York: Springer, 1972: 283-335.
16. Chen YL, Huang TF, Chen SW, Tsai IH. Determination of the structure of two novel echistatin variants and comparison of the ability of echistatin variants to inhibit aggregation of platelets from different species. Biochem J 1995; 305: 513-20.
17. Damiano BP, Mitchell JA, Giardino E, Corcoran T, Haertlein BJ, de Garavilla L, Kauffman JA, Hoekstra WJ, Maryanoff BE, Andrade-Gordon P. Antiplatelet and antithrombotic activity of RWJ-53308, a novel orally active glycoprotein IIb/IIIa antagonist. Thromb Res 2000; 104: 113-26.
18. Coller BS, Anderson K, Weisman HF. New antiplatelet agents: Platelet GPIIb/IIIa antagonists. Thromb Haemost 1995; 74: 302-8.
19. Hirose H, Kimura T, Okada M, Itoh Y, Ishida F, Mochizuki N, Nishibe T, Nishikibe M. Antiplatelet and antithrombotic effects of a novel selective phosphodiesterase 3 inhibitor, NSP-513, in mice and rats. Jpn J Pharmacol 2000; 82: 188-98.
20. Antonopoulou S, Demopoulos CA, Iatrou C. Blood cardiolipin in haemodialysis patients. Its implication in the biological action of platelet-activating factor. Int J Biochem Cell Biol 1996; 28: 43-51.
21. Nordoy A, Chandler AB. Platelet thrombosis induced by adenosine diphosphate in the rat. Scand J Haematol 1964; 1: 16-21.
22. Kulkarni S, Dopheide SM, Yap CL, Ravanat C, Freund M, Mangin P, Heel KA, Street A, Harper IS, Lanza F, Jackson SP. A revised model of platelet aggregation. J Clin Invest 2000; 105: 783-91.
23. Beviglia L, Poggi A, Rossi C, McLane MA, Calabrese R, Scanziani E, Cook JJ, Niewiarowski S. Mouse antithrombotic assay. Inhibition of platelet thrombolism by disintegrins. Thromb Res 1993; 71: 301-6.
24. Sheu JR, Yen MH, Peng HC, Chang MC, Huang TF. Triflavin, an Arg-Gly-Asp-containing peptide, prevents platelet plug formation in in vivo experiments. Eur J Pharmacol 1995; 294: 231-7.
25. Jancinova V, Petrikova M, Majekova M, Nosal R. Effect of pheniramine, chlorpheniramine and brompheniramine on stimulated blood platelet: Structure-activity relationships. Inflamm Res 1995; 44: S38-9.